Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: naproxen

Celecoxib Is a Safe Treatment for Arthritis

Lara C. Pullen, PhD  |  February 20, 2017

A study compared celecoxib with ibuprofen and naproxen to determine its cardiovascular safety, as well as gastrointestinal and renal outcomes, in patients with rheumatoid arthritis and osteoarthritis. The results showed that celecoxib met all prespecified noninferiority requirements and is as safe as other non-selective NSAIDs…

Filed under:Drug Updates

Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

Michele B. Kaufman, PharmD, BCGP  |  December 13, 2016

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

Filed under:AnalgesicsDrug UpdatesResearch Rheum Tagged with:anti-inflammatorycardiovascularcelecoxib (Elyxyb)drugFDAmortalityNSAIDoutcomePrecision trialResearchrheumatologyriskSafety

Rheumatology Coding Corner Year-End Quiz Questions

From the College  |  December 13, 2016

A 38-year-old female patient returns to the practice for the second of three hyaluronate sodium injections of the left knee. The patient states the pain is somewhat better after her last injection. Her weight is 165 lbs., her height is 5 feet 6 inches, and her blood pressure is 120/81. After discussing the risks of…

Filed under:From the CollegePractice Support Tagged with:BillingCodingpatient carePractice Managementrheumatology

Celecoxib & Cardiovascular Death: NSAID Safety Under Review

Michele B. Kaufman, PharmD, BCGP  |  December 7, 2016

A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

Filed under:AnalgesicsDrug Updates Tagged with:cardiovascularFDAFood and Drug AdministrationheartNSAIDsPREC

Africa Studio/shutterstock.com

Evidence Needed to Support Marijuana Use for Pain Relief in Rheumatologic Conditions

Vanessa Caceres  |  October 10, 2016

With the chronic pain and other health issues that many rheumatology patients face every day, it’s natural for rheumatologists and their patients to wonder if cannabinoid treatments are of any help. At this point, there is insufficient evidence to recommend cannabinoid treatments to manage rheumatic diseases, according to a review article published in the May…

Filed under:ConditionsPain SyndromesResearch Rheum Tagged with:cannabinoidFibromyalgiamarijuanaOsteoarthritisPainpatient careResearchRheumatic DiseasetherapyTreatment

Lilly Says New Type of Pain Drug Could Reduce Need for Opioids

Ransdell Pierson  |  May 28, 2016

(Reuters)—Eli Lilly and Co. on Tuesday said it and partner Pfizer Inc. aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain. The Indianapolis drugmaker said tanezumab, given by injection every eight weeks, could be a far…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painOpioidsosteoarthritis (OA)PainPain Managementtanezumab

Heart Disease: Major Risk Factor for Many Rheumatology Patients

Vanessa Caceres  |  October 14, 2015

Rheumatic diseases, such as rheuma­toid arthritis (RA), systemic lupus erythematosus (SLE) and vasculitis, can affect the body in many ways, but perhaps the most serious is the increased risk of heart disease for many patients. As the risk of atherosclerosis in autoimmune disease patients gains increased attention, rheumatologists and cardiologists are collaborating more often to…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiologistsClinicalHeart Diseasepatient careRARheumatoid arthritisrheumatologistrisk

Connective Tissue Disorders Lack Societal Concern, Financial Support

Simon M. Helfgott, MD  |  September 15, 2015

“Love is the bone and sinew of my curse.” —Sylvia Plath Cutting the Cord Here’s the problem: No one grows up wanting to seek the cure for bursitis—or tendonitis or just about any of the other seemingly mundane maladies afflicting our body’s scaffolding. Meniscal tears, fasciitis, tendinopathies—the list is endless. Chances are, your college essay…

Filed under:ConditionsOpinionResearch RheumRheuminationsSoft Tissue PainSpeak Out Rheum Tagged with:bursitisconnective tissue disorderpatient careResearchrheumatologisttendonitis

Juvenile Idiopathic Arthritis: Parents Discuss Challenges, Support Rheumatologists Can Offer

Kathy Holliman  |  September 15, 2015

One parent wishes that she could have consulted a crystal ball at the beginning of her daughter’s illness to have “some kind of idea of what we were in for. There are so many stages of letting go of the idea of what your little kid is in for in life, what they are going…

Filed under:EthicsProfessional Topics Tagged with:education and trainingEthicspatient carerheumatologists

FDA Strengthens Warning Label for Certain Antiinflammatory Drugs

Reuters Staff  |  July 14, 2015

(Reuters)—The U.S. Food and Drug Administration is strengthening an existing warning label that non-aspirin, non-steroidal antiinflammatory drugs (NSAIDs) increase the risk of heart attack or stroke. NSAIDs include ibuprofen, naproxen, diclofenac and celecoxib, all of which carry FDA warning labels. The agency said it would require updates to the labels of prescription and over-the-counter (OTC)…

Filed under:AnalgesicsDrug Updates Tagged with:Drug SafetyFDANonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDssafety warning

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences